Toronto, Ontario–(Newsfile Corp. – May 15, 2020) – Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) (“Relay” or the “Company“), and Fio Corporation (“Fio”) are pleased to announce the signing of a memorandum of understanding (“MOU” or the “Agreement”) to define a mutually beneficial collaboration to accelerate the enhancement of Fio’s Data-Device Platform as a COVID-19 testing, data collection and reporting platform.
Under the terms of the agreement Relay will provide expertise in medical technology development and commercialization as well as the integration of compatible and complementary assets from its portfolio including HemoPalm Corp. and Pharmatrac technologies to enhance Fio’s data-device platform for COVID-19 testing regimes using third-party rapid diagnostic tests (RDT). Fio’s technology has been proven for community-based RDT testing, triage, and tracking to manage outbreaks of high-consequence infectious diseases, such as malaria, HIV, dengue, and others.
The objective of the MOU is for the companies to jointly form a plan and partnership for the rapid expansion of Fio’s platform to encompass multiple emerging COVID-19 tests. The companies will assess and establish a collective infrastructure for the advancement and pursuit of commercial opportunities related to the project with the intent to execute a definitive agreement within 60 days from signing.
During the MOU period both companies will allocate resources to the project and Relay will provide development resources including its extensive expertise in medical device development, regulatory strategy, diagnostics, software and artificial intelligence, project management and its lab, workshop, and office space to support the growing operational requirements of the partnership.
“The COVID-19 situation will evolve – new and more tests, new triage procedures, new treatments, and ups and downs in threat patterns. In this time, a safe return to social and economic life can be accomplished only by new, rapid, and flexible technological responses. This requires companies to combine capabilities for a common purpose, which is what Relay and Fio are doing.” said Dr. Michael Greenberg, CEO of Fio Corporation.
“It is clear that COVID-19 will continue to present multiple healthcare challenges before we move into the next phase of recovery and we are very excited to participate in the delivery of a meaningful technological solution to potentially give individuals, families and governments the confidence required to return to day-to-day life, and do so safely as we continue to fight the pandemic.” said Yoav Raiter, CEO, Relay Medical Corp.
“Fio’s data-device platform, Fionet, offers an elegant and powerful way to solve many COVID-19 testing problems, from the administration of efficient serological surveys that enable public health decision making, to the practical assurance of biosecurity at work, public, and educational facilities. Relay’s HemoPalm team looks forward to working with Fio to create optimized solutions for these challenges.” said Paul Glavina, VP In Vitro Diagnostics, Relay Medical Corp.
On April 29, 2020 Fio Corporation, with Relay as a joint-venture partner, filed a proposal to Innovative Solutions Canada through the COVID-19 Testing Stream Call for Proposals for a grant to test a jointly developed COVID-19 antibody testing platform with a federal government organization.
Need for distributed COVID-19 testing using RDTs
Rapid diagnostic tests are being developed for active infections targeting antigens of the COVID-19 virus and for detecting past infections and immune response by detecting the presence of specific antibodies. These tests are typically lateral flow rapid diagnostic strips, similar to an over-the-counter pregnancy test, and offer low-cost and simple operation and can be manufactured at high volumes. However, such tests suffer from several issues including lack of automation and a requirement for visual human interpretation to determine the outcome. In a mass testing regime, manual interpretation can have significantly high error rates, and documenting and communicating the results is not streamlined and is subject to transcription errors. Given the importance of the data, tools which can help reduce error rates, automate interpretation, and collate results are needed to facilitate safe and effective mass testing of the population for disease presence and exposure.
Details of Fionet Platform
To view an enhanced version of this , please visit:
Fio’s platform enables distributed testing and automated aggregation of diagnostic data from multiple diagnostic devices that can support public health decisions with accurate, real-time data. Its components are:
• Fio Deki Mobile Device
- A rugged mobile RDT reader that improves diagnostic quality and testing accuracy
- Includes procedures and protocols for running approved RDT tests
- Machine interpretation of RDT tests
- Compatible with third-party diagnostic tests, devices, and laboratory instruments.
- Real-time data capture and geotagging
• Fionet Cloud
- Device connectivity even in areas with poor connectivity
- Seamless data exchange with 3rd party health databases
- Secure, encrypted storage of private health data
- Remote updating of protocols and software to Fio Mobile devices
• Fionet Online Portal
- Oversight of testing results and protocol adherence
- Intervention planning with real-time, anonymous epidemiological data
- Track and evaluate resource allocation and efficiency
The Company’s platform has been deployed in 12 countries where frontline healthcare workers have benefitted 1 million patients for testing, triage, and management of diseases such as Malaria and HIV. The information collected from these health visits resulted in over 50 million data points that were available in near real-time for Public Health managers. With Fionet, public health authorities were able to reduce diagnostic errors, ensure correct testing and clinical procedures, monitor performance, capture data and support supply chain management1.
COVID-19 Pandemic Adaptation
Fio and Relay’s collective aim is to offer a system that is automated and ready to perform mass distributed testing, triage, and tracking for COVID-19 organized by public health agencies and private sector companies. This will require efforts to customize the Fio platform for specific COVID-19 approved third-party RTDs and ensure that the device is compliant with FDA, Health Canada, and other medical device standards. Innovations are envisioned to expand the software’s security, workflow, throughput, and data capture for mass serological surveillance programs.
**The Companies are not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
1Adah, P., Maduka, O., Obasi, O. et al. The role of the Deki Reader™ in malaria diagnosis, treatment and reporting: findings from an Africare pilot project in Nigeria. Malar J 17, 221 (2018). https://doi.org/10.1186/s12936-018-2356-8
About Fio Corp.
Fio Corporation, privately held and headquartered in Toronto, developed and markets the world’s first integrated guidance & tracking IT platform for decentralized healthcare settings, a new category of solution that raises healthcare quality and lowers healthcare costs. The platform enables average healthcare workers in clinics to deliver a new level of quality-controlled diagnostic testing and case management. Simultaneously, as an automated by-product of its clinical use, the platform captures and provides unprecedented frontline data to remote supervisors and stakeholders, enabling real-time remote tracking, insight distribution, and intervention. Fio operates globally in partnership with local distribution, service, and support organizations and also partners with other companies that license its technologies.
About Relay Medical Corp.
Relay Medical is a MedTech innovation Company headquartered in Toronto, Canada focused on the development of novel technologies in the diagnostics and AI data science sectors.
W. Clark Kent
Relay Medical Corp.
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
EU Investor Relations
Office. +49 (0) 177 774 2314
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the commercialization plans for HemoPalm Corp. described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/55976
Materia and Pure Ratios to Launch Award-Winning CBD Topicals into the UK Market
Materia (“Materia” or the “Company“), a medical cannabis and CBD wellness company focused on the European market, today announced an agreement with Pure Ratios Holdings Inc. (“Pure Ratios”), an award-winning CBD topical manufacturer and subsidiary of 4Front Ventures Corp (CSE: FFNT) (OTCQX: FFNTF), to distribute and market its products across Europe.
“Pure Ratios is an innovator, with a best-in-class transdermal patch, rooted in science and natural medicine. We are excited to be their European partner, with plans to launch in the UK as our first market,” said Deepak Anand, CEO of Materia. “The UK is currently Europe’s largest CBD market and consumers are developing brand preference for products they like and trust. The market research we have conducted, including consumer segmentation and brand mapping, has made clear the calibre of partners required for long-term success. With highly differentiated products, proven quality and an established track record with consumers, Pure Ratios fits this profile perfectly.”
Founded in 2015 and based in San Diego, California, Pure Ratios is known for combining holistic wellness concepts with CBD and other cannabinoids. Its award-winning line of CBD topical patches are sold through a network of over 1000 stores across the United States and through their expanding e-commerce and distribution platforms. Under the terms of the agreement, Materia will conduct sales and marketing for Pure Ratios’ hemp-derived CBD topical salve, topical roll-on, lip balm and 96-hour transdermal reservoir patch products. Materia will work directly with wholesalers, retailers, and direct to consumers channels in the UK.
“Our approach of combining modern cannabis science with natural holistic medicine is both unique and effective and that has helped establish Pure Ratios as one of the most reputable CBD brands in the US,” said Chad Conner, Co-Founder of Pure Ratios. “We selected Materia as our partner because they have the commercial acumen and regulatory expertise to help navigate the burgeoning European market opportunity for us to propel Pure Ratios into a leading global wellness brand.”
According to the Centre for Medical Cannabis, UK consumers are spending over £300 million a year on CBD products and the market is forecasted to grow to almost £1 billion by 20251. Demand for topicals is expected to exceed overall growth in the CBD market with a CAGR greater than 20%1. Key topical formats are balms and gels that are being used for muscle and joint relief, as well as skincare creams. The global CBD skincare market alone is expected to expand at a CAGR of 32.9% from 2019 to 2025, thereby reaching a value of approximately £1.4 billion (USD $1.7 billion) by 20252.
InnoCan Pharma Collaborate with Recipharm on its CBD Loaded Exosome (CLX) Treatments
Herzeliya, Israel and Calgary, Alberta–(Newsfile Corp. – July 9, 2020) – InnoCan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce its collaboration with Recipharm, Israel to synthesize and analyze cannabinoid loaded exosomes.
Recipharm unites more than 30 facilities across 10 different countries offering a range of services, mainly in two different operating areas, pharmaceutical development services and manufacturing services. Recipharm offers seamless tech transfer from Recipharm development facilities and provide commercial supply of a wide range of formulations. Recipharm has over 25 years of experience innovating and developing new technologies and processes for clinical applications. Recipharm’s facility in Israel, offers development services to a wide variety of clients from start-ups to large established companies. Recipharm offers a wide range of GMP-compliant services ranging from manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices.
Iris Bincovich, InnoCan’s CEO stated: “Working closely with the exceptional Recipharm team will allow InnoCan Pharma to devote efforts with the exosome technology production/loading technology while the work on the cannabinoids themselves will be done at Recipharm.”
Dr. Sylvia Kachalsky, site manager in Israel stated: “We are very exiting to work with InnoCan Pharma on this unique project who has a potential to be applied on large spectrum of different indications. The idea of loading Exosomes with Cannabinoids may open a wide window to different formulations, using the Exosome as a “targeted missile” leading the chosen Cannabinoid to its target.”
Prof. Dani Offen stated: “The development of the CLX- CBD loaded Exosome is very challenging but holding huge potential. Working with Recipharm will allow me and my team to be concentrating and putting all efforts at the Exosome production/characterization/loading side of the development process while knowing the analysis work is been done in one of the best labs we could chose. We are working with Recipharm in close collaboration on the development of this exiting technology and looking forward to achieve the milestones as we planned.”
About Innocan Pharma
The Company, through its wholly-owned subsidiary, Innocan Pharma Ltd. (“Innocan Pharma Israel“), is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD“) with other pharmaceutical ingredients. Innocan and Ramot at Tel Aviv University are collaborating on the development of a new exosome-based technology that targets both central nervous system indications and the COVID-19 coronavirus. CBD-loaded exosomes may hold the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.
Innocan Pharma Israel has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. The Company, together with Prof. Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, plans to test the liposome platform on several potential indications. The Company is also working on a dermal product integrating CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately Euro 1.1 Billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For further information, please contact:
Innocan Pharma Corporation
Iris Bincovich, CEO
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution regarding forward-looking information
Certain information set forth in this news release is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan are available under Innocan’s profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan Pharma does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/59362
TransCanna Announces Launch of Lyfted Apparel Line
Vancouver, British Columbia–(Newsfile Corp. – July 8, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (“TransCanna” or the “Company“) announces that its wholly-owned subsidiary Lyfted Farms Inc. announces the launch of Lyfted Apparel line.
Lyfted Farms is thrilled to announce the launch of its own exclusive line of t-shirts, hoodies, caps, and other apparel and branded items. Lyfted Farms has contracted local artists to produce over 15 new designs that reflect the vibes of authentic California cannabis culture.
The new items can be found at www.lyftedfarms.com/apparel or on Instagram @lyftedfarmsapparel
Lyfted Farms has executed a Memorandum of Understanding with Raymond Willis, Founder, and CEO of Kingpin Skateboard and Apparel, to market and promote the new Lyfted Apparel line. Raymond brings more than 20 years of experience in the industry and favors exciting and creative ways to share the brand with a broader audience.
“I really love doing fun promotions where not only do you get to purchase the brands you love but also get to be a part of something bigger. Our first promotion for Lyfted Apparel will hit this month and feature a raffle the winner of which will spend an afternoon with Bay-Area Rapper Nump!” stated Raymond Willis.
In addition, the Company announces that it has entered into a Consulting Services Agreement with 1236686 B.C. Ltd. Pursuant to the Agreement, 1236686 B.C. Ltd. will provide consulting advice and services in connection with the development and operation of the corporate and financial affairs of the Company, its subsidiaries, and its affiliates. The Company will issue to 1236686 B.C. Ltd., 400,000 common shares for a deemed value of $296,000.
Additionally, the Company has elected not to renew the contract for its CFO, Michele Pillon. It is pleased to announce that Gary Khangura, CPA will act as “Interim” Chief Financial Officer as the Company seeks to recruit a Chief Financial Officer with a firm understanding of the cannabis industry in the California Marketplace. The Company thanks Ms. Pillon for her work during the Covid19 pandemic and assisting the Company in completing its audit during the extended deadlines.
The Company announces the resignation of Stephen Giblin as a director of the Company. Mr. Giblin has been appointed to the Company’s Advisory Board, the Company thanks Mr. Giblin for his time served.
About TransCanna Holdings Inc.
TransCanna Holdings Inc. is a California based, Canadian listed, Company building cannabis-focused brands for the California lifestyle, through its wholly-owned California subsidiaries.
On behalf of the Board of Directors
Bob Blink, CEO
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/59430
Cannabis3 weeks ago
RETRANSMISSION: Hemp, Inc. Announces that Its First Ever Great American Hempathon is in Full Swing
Cannabis4 weeks ago
Hemp, Inc. Rapidly Approaching $2 Million in Sales from Its Premium, High Quality Hemp Flower
Cannabis3 weeks ago
Banksy Collection Becomes Permanent Installation at Toronto’s Newest Cannabis Store
Cannabis3 weeks ago
Hemp, Inc. Announces Newly Enhanced King of Hemp Website
Cannabis4 weeks ago
From Solar to Hemp SinglePoint Continues to Drive Headlines and Increase Sales, Brand Recognition is Reaching New Heights as Articles and Interviews Publish
Cannabis4 weeks ago
Fountain Asset Corp. Announces Its Financial Results for the Quarter and Year Ended December 31, 2019
Cannabis4 weeks ago
XPhyto’s Diagnostic Partners Receive BMBF Grant for Infectious Disease Screening Tests
Cannabis3 weeks ago
XPhyto Therapeutics Corp.: Infectious Disease Oral Screening Test Advancement